Combining Color and Morphology Improves Identification of Low-Grade Urothelial Cancer Cells

Similar documents
A novel urine cytology stain for the detection and monitoring of urothelial carcinoma

A NOVEL URINE CYTOLOGY STAIN FOR THE DETECTION AND MONITORING OF UROTHELIAL CARCINOMA. Running head: A Novel Stain For The Detection Of Bladder Cancer

Meir Medical Center, Kfar Saba and Sackler School of Medicine, Tel-Aviv University, Dept. of Urology, Tel-Aviv, Israel 5

Toyonori Tsuzuki MD, PhD Professor and Chair Department of Surgical Pathology Aichi Medical University Hospital

Urinary Cytology. Spasenija Savic Prince, MD Pathology, University Hospital Basel, Switzerland

The application of cytology in urological diseases

Afterword: The Paris System for Reporting Urinary Cytology

Rationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm

Application of Urovision FISH testing for diagnosis of bladder cancer

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Index 179. Genital tract contaminants, 17, 20, 22, 150 papilloma virus-infected cells, 47 squamous cells, sources of, 7

MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment

Kidney, Bladder and Prostate Neoplasia. David Bingham MD

Urinary Cytology. Spasenija Savic Prince Pathology, University Hospital Basel, Switzerland

BLADDER CANCER: PATIENT INFORMATION

American Society of Cytopathology Core Curriculum in Molecular Biology

Accuracy of Urine Cytology and the Significance of an Atypical Category

Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice

Impact of Implementing the Paris System for Reporting Urine Cytology in the Performance of Urine Cytology A Correlative Study of 124 Cases

The difference in cancer detection

The Use of Drug Eluting Stents in Regular Clinical Practice did not Reduce the Clinical Restenosis Rate Compared to Bare Metal Stents.

Bladder Case # 1. Principal Diagnosis: Bladder Tumor, Suspect Transitional Cell Carcinoma. Secondary Diagnoses: 1. Hypertension. 2. Hyperlipidemia.

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules

by Non-invasive Imaging Pei-Gen Ren, Sheen-Woo Lee, Sandip Biswal, Stuart Goodman Stanford University, Stanford

Advanced Pathophysiology Unit 7: Renal-Urologic Page 1 of 6

Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency

Controversies in the management of Non-muscle invasive bladder cancer

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION CYTOPATHOLOGY Monday, April 26, 2013 FACULTY COPY

THE CLASSIFICATION OF BLADDER TUMOURS

Renal tumors of adults

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Diagnosis and classification

Award Top Quizzes For Residents

Cystoscopy in children presenting with hematuria should not be overlooked

Histopathology: Cervical HPV and neoplasia

BC Cancer Cervix Screening 2015 Program Results. February 2018

Synonyms. Nephrogenic metaplasia Mesonephric adenoma

Anti-hTERT Antibody (SCD-A7)

Dr. Issraa Ali Hussein

Objectives. Salivary Gland FNA: The Milan System. Role of Salivary Gland FNA 04/26/2018

Bladder Cancer Diagnostic Tests

Clinical Practice Guidelines June 2013

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018

Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

Correlation of Abnormal Liver Function Tests in Patients with Severe Heart Failure to Outcomes.

Audit of reporting of thyroid cytology specimens and their correlation with thyroid histology. A Bartlett, TS Bracey, T Malik

Thursday, 23 rd November, 2017

April 26 th April 29 th, 2017 Kibbutz Hagoshrim, Israel WEDNESDAY, APRIL 26, rd International Congress on Molecular Targeting Therapy

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

ISRAELI NEUROENDOCRINE TUMORS PROGRAM

Cytyc Corporation - Case Presentation Archive - July 2002

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

Cytopathology. Robert M Genta Pathologie Clinique Université de Genève

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

A patient with recurrent bladder cancer presents with the following history:

Cytology Update M Laing QEUH

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Histological Typing Of Cancer And Precancer Of The Oral Mucosa

Normal Morphology. Anatomic Considerations. Normal Urothelial Histology and Cytology

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

NPQR 2018 Qualified Clinical Data Registry (QCDR) Measures 21_18247_LS.

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor

ACCME/Disclosures. Cribriform Lesions of the Prostate. Case

S20 - Outcome of Coronary Interventions in Complex Lesions and Patients

Cellular Pathology Of Glandular Lesions And Uncommon Neoplasms Of The Cervix By Glenn McCluggage;John Tidy;John Smith READ ONLINE

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

International Journal of Health Sciences and Research ISSN:

PAAF vs Core Biopsy en Lesiones Mamarias Case #1

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Transitional Cell Carcinoma of the Renal Pelvis The Diagnostic Role of Pelvic Washings

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

ASYMPTOMATIC MICROSCOPIC HEMATURIA IN WOMEN JOLYN HILL, MD ASSISTANT PROFESSOR, CLINICAL UROGYNECOLOGY FEBRUARY14, 2017

Bladder cancer (BC) is the fifth most commonly diagnosed malignancy in the United

December 22, Earl Berman, MD Attn Medical Review Two Vantage Way Nashville, TN

117 Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice. Gregory Flynn MD

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION

International Journal of Biological & Medical Research

Clinically Microscopically Pathogenesis: autoimmune not lifetime


Cytology for the Endocrinologist. Nicole Massoll M.D

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia

Vagina. 1. Introduction. 1.1 General Information and Aetiology

Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000

Department of Pathology, Kathmandu Medical College & Teaching Hospital, Sinamangal, Kathmandu, Nepal

Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation

Cervical Precancer: Evaluation and Management

Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS

International Journal of Health Sciences and Research ISSN:

Cytyc Corporation - Case Presentation Archive - October 2001

Ivyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract

Transcription:

Combining Color and Morphology Improves Identification of Low-Grade Urothelial Cancer Cells Alexander Shtabsky 1, Sylvia Lew 2, Ronny Rona 3, Noa Davis 4, Yoram Mor 5, Uri Lindner 6, Ofer Nativ 7, Ofer Gofrit 8, Ilan Leibovitch 9, Haim Matzkin 10, Ami Sidi 11, Michael Cohen 12, Ofer Yossepovitch 13 1 Institute of Pathology, Sourasky Medical Center, Tel Aviv Univ., Tel Aviv, Israel; 2 Patho-Lab Diagnostics Ltd, Ness Ziona, Israel; 3 Former member of the Cytology unit, Meir Medical Center, Kfar Saba, Israel; 4 Micromedic Technologies Ltd., Tel Aviv, Israel; 5 Department of Urology, Sheba Medical Center, Tel Aviv, Israel; 6 Department of Urology, Kaplan Medical Center, Rehovot, Israel; 7 Department of Urology, Bnai Zion Medical Center, Haifa, Israel; 8 Department of Urology, Hadassah Medical Center, Jerusalem, Israel; 9 Department of Urology, Meir Medical Center, Kfar Saba, Israel; 10 Department of Urology, Sourasky Medical Center, Tel Aviv, Israel; 11 Department of Urology, Wolfson Medical Center, Holon, Israel; 12 Department of Urology, HaEmek Medical Center, Afula, Israel; 13 Department of Urology, Rabin Medical Center, Petach Tikva, Israel

Technology Principles CellDetect histochemical stain has been demonstrated to differentiate between normal and neoplastic cells by color alongside morphological features Using a proprietary plant extract and generic dyes, the stain colors the nuclei of neoplastic cells in reddish-purple, while normal cell nuclei are stained in green or blue 2

Assumed Mechanism of Action The discriminative capacity of the stain is most likely related to the increased metabolic activity observed in cancer cells Based on differential ph affinity, the combination of dyes enables color discrimination, which is accentuated and stabilized by the plant extract The CellDetect stain is applicable to different specimens including histological tissues and cytological smears LG, Ta LG, T1 3

Cell Transformation in Tissue Culture Normal cells Following oncogenic transformation Suppression of oncogenic properties Normal cells Transformed foci The staining technology is able to pick up early transformation events 4 Sagiv I, Idelevich P, Rivkin I, Margalit R, Elkeles A, Levitzki A. A color discriminating broad range cell staining technology for early detection of cell transformation. Journal of Carcinogenesis 2009; 8:16-23

Rat Brain Glioblastoma in Frozen Sections Gross morphological detection of Rat brain Glioblastoma in frozen sections Giemsa H&E CellDetect 5 Zetiq, unpublished findings

Open Label Clinical Study 58 archived bladder biopsies and 44 urine samples stained with CellDetect 100% concordance between H&E and CellDetect The sensitivity of detecting urothelial carcinoma in urine smears was 94% and the specificity 89% 6

7 Objective Prospective Blinded Multicenter Study To further explore the performance of CellDetect in urine specimens Methods The study was conducted in nine hospitals enrolling patients monitored for history of urothelial carcinoma Voided urine samples collected prior to routine cystoscopic surveillance or TURT/cystectomy The cytospin smears were blindly observed by at least two cytology experts The findings were compared to the histological diagnoses in positive cases and to cystoscopy and/or histology in negative cases

Normal Urine 50 m 8

9 Normal Urine

10 Normal Urine

Benign Urothelial, Squamous & Inflammatory Cells 50 m 11

Low Grade Urothelial Carcinoma 50 m 12

13 Low Grade Urothelial Carcinoma

14 Low Grade Urothelial Carcinoma

High Grade Urothelial Carcinoma 50 m 15

16 High Grade Urothelial Carcinoma

17 High Grade Urothelial Carcinoma

High Grade Urothelial Carcinoma High Grade Urothelial Carcinoma 18

Results of Blinded Multicenter Study Study population - 217 subjects : 121 negative (normal appearing bladder / negative histology) 96 cancer cases (positive histology) Cancer Grade Nº of cases Cancer Stage Nº of cases LG 41 Ta 50 HG 54 T1, TIS 22 Undetermined 1 T2 22 Total 96 Undetermined 2 Total 96 Each slide was analyzed by at least two independent cytology experts who were blinded to patient true diagnosis Categories for diagnosis were: Negative, Reactive/Inflammatory, Suspicious, Highly suspicious and Positive Based on statistical analysis, cutoff for positive was Suspicious and up 19

Results of Blinded Multicenter Study Sensitivity Specificity* Nº of cases 96 121 CellDetect (n=217) 84% 83% * Adjusted to disease prevalence of 10% among monitoring population Sensitivity stratified by tumor stage Ta T1, CIS T2 Nº of cases 50 21 22 Sensitivity 80% 85% 82% Sensitivity stratified by tumor grade LG HG Nº of cases 41 54 Sensitivity 78% 89% 20

Conclusions CellDetect stain demonstrates high sensitivity for both low & high grade bladder cancer tumors, which is of particular importance for the former The findings suggest that CellDetect can be further developed to provide a non-invasive alternative to cystoscopic surveillance for the early detection of bladder cancer recurrence Further investigation is warranted to evaluate the performance of CellDetect for the diagnosis of bladder cancer in suspected patients with hematuria and in instrumentation specimens Reactive atypia in nephrolithiasis, chemotherapy-induced changes, BK (polyoma virus) nephropathy, papillary urothelial neoplasm of low malignant potential and some other clinical cases are subject of further investigation 21

Publications Davis et al. A novel urine cytology stain for the detection and monitoring of bladder cancer. The Journal of Urology 2014; 192:1628-1632 He et al. Application of the CellDetect staining technique in diagnosis of human cervical cancer. Gynecologic Oncology 2014; 132:383-388 Idelevich et al. Screening for cervical neoplasia: a community-based trial comparing Pap staining, human papilloma virus testing, and the new bi-functional CellDetect stain. Diagnostic Cytopathology 2012; 40:1054-61 Idelevich et al. Novel dual-function CellDetect staining technology: wedding morphology and tinctorial discrimination to detect cervical neoplasia; Diagnostic Pathology 2010; 5:70 Sagiv et al. A color discriminating broad range cell staining technology for early detection of cell transformation. Journal of Carcinogenesis 2009; 8:16-23 Idelevich et al. Novel Histochemichal Stain for Tinctorial Detection of Cancer and Neoplastic Cells. The Journal of Histotechnology 2009; 32:97-105 22

23 Thank you